Subtopic Deep Dive
Renal Stent Placement Outcomes
Research Guide
What is Renal Stent Placement Outcomes?
Renal stent placement outcomes evaluate restenosis rates, renal function preservation, and procedural complications following renal artery stent implantation for renovascular disease.
Studies assess bare-metal and drug-eluting stents in atherosclerotic and fibromuscular dysplasia-related stenoses, reporting patency rates and renal function changes. Meta-analyses stratify outcomes by lesion characteristics and patient comorbidities (Radermacher et al., 2001, 772 citations; Watson et al., 2000, 257 citations). Over 10 key papers from 1991-2019 document intermediate-term follow-up and revascularization efficacy.
Why It Matters
Renal stent outcomes determine patient selection for revascularization in renal artery stenosis, guiding hypertension control and kidney preservation strategies (Trinquart et al., 2010). Long-term patency data from stenting trials inform designs for novel therapies like mesenchymal stem cell adjuncts in atherosclerotic renal artery stenosis (Eirin et al., 2012). Procedure complication rates influence risk stratification in fibromuscular dysplasia management (Olin and Sealove, 2011; Plouin et al., 2007).
Key Research Challenges
Predicting Stent Patency
Restenosis rates vary by lesion type, with elastic recoil post-angioplasty requiring stents (Rees et al., 1991). Doppler ultrasonography identifies non-responders via resistance index ≥80, limiting functional improvements (Radermacher et al., 2001). Intermediate-term follow-up shows variable renal size preservation (Watson et al., 2000).
Renal Function Preservation
Stenting preserves renal function in select atherosclerotic renovascular disease cases but fails in high-resistance cases (Watson et al., 2000). Comorbid chronic kidney disease worsens revascularization outcomes (Cooper et al., 2006). Fibromuscular dysplasia responds better to angioplasty with stenting (Trinquart et al., 2010).
Lesion-Specific Complications
Ostial atherosclerotic stenoses treated with Palmaz stents show restenosis risks (Rees et al., 1991). Fibromuscular dysplasia management lacks standardized stent protocols (Olin and Sealove, 2011). Patient selection using pre-procedure metrics remains inconsistent (Radermacher et al., 2001).
Essential Papers
Use of Doppler Ultrasonography to Predict the Outcome of Therapy for Renal-Artery Stenosis
Jörg Radermacher, Ajay Chavan, Jörg S. Bleck et al. · 2001 · New England Journal of Medicine · 772 citations
A renal resistance-index value of at least 80 reliably identifies patients with renal-artery stenosis in whom angioplasty or surgery will not improve renal function, blood pressure, or kidney survi...
Chronic Kidney Disease and Coronary Artery Disease
Mark J. Sarnak, Kerstin Amann, Sripal Bangalore et al. · 2019 · Journal of the American College of Cardiology · 659 citations
Impact of Renal Dysfunction on Outcomes of Coronary Artery Bypass Surgery
William A. Cooper, Sean M. O’Brien, Vinod H. Thourani et al. · 2006 · Circulation · 490 citations
Background— Although patients with end-stage renal disease are known to be at high risk for mortality after coronary artery bypass graft (CABG) surgery, the impact of lesser degrees of renal impair...
Implantation and intermediate-term follow-up of stents in congenital heart disease.
Martin P. OʼLaughlin, Michael Slack, Ronald G. Grifka et al. · 1993 · Circulation · 329 citations
BACKGROUND Balloon-expandable stents (Johnson and Johnson Interventional Systems) have been in use for congenital heart disease since late 1989. They have made possible treatment in previously untr...
Fibromuscular dysplasia
Pierre‐François Plouin, Jérôme Perdu, Agnès La Batide-Alanore et al. · 2007 · Orphanet Journal of Rare Diseases · 281 citations
Fibromuscular dysplasia (FMD), formerly called fibromuscular fibroplasia, is a group of nonatherosclerotic, noninflammatory arterial diseases that most commonly involve the renal and carotid arteri...
Diagnosis, management, and future developments of fibromuscular dysplasia
Jeffrey W. Olin, Brett Sealove · 2011 · Journal of Vascular Surgery · 268 citations
Efficacy of Revascularization For Renal Artery Stenosis Caused by Fibromuscular Dysplasia
Ludovic Trinquart, Claire Mounier‐Véhier, Marc Sapoval et al. · 2010 · Hypertension · 259 citations
In patients with fibromuscular dysplasia and renal artery stenosis, renal artery revascularization has been used to cure hypertension or to improve blood pressure control. To provide an up-to-date ...
Reading Guide
Foundational Papers
Start with Radermacher et al. (2001, 772 citations) for Doppler prediction of therapy failure, then Rees et al. (1991, 249 citations) for early Palmaz stent ostial outcomes, and Watson et al. (2000, 257 citations) for renal function/size effects.
Recent Advances
Study Trinquart et al. (2010) for fibromuscular dysplasia revascularization efficacy and Eirin et al. (2012) for MSC-improved outcomes in atherosclerotic stenosis.
Core Methods
Palmaz balloon-expandable stents for ostial lesions (Rees et al., 1991); Doppler resistance index for patient selection (Radermacher et al., 2001); intermediate angiographic follow-up for patency (O’Laughlin et al., 1993).
How PapersFlow Helps You Research Renal Stent Placement Outcomes
Discover & Search
Research Agent uses searchPapers and citationGraph on Radermacher et al. (2001) to map 772-cited works on Doppler prediction of renal stent outcomes, then exaSearch for 'renal artery stent restenosis fibromuscular dysplasia' and findSimilarPapers to uncover Trinquart et al. (2010) equivalents.
Analyze & Verify
Analysis Agent applies readPaperContent to extract restenosis rates from Rees et al. (1991), verifies claims with CoVe chain-of-verification against Watson et al. (2000), and runs PythonAnalysis with pandas to meta-analyze renal function deltas across Cooper et al. (2006) datasets, graded by GRADE for evidence quality.
Synthesize & Write
Synthesis Agent detects gaps in long-term ostial stent data via contradiction flagging between Rees et al. (1991) and Eirin et al. (2012), while Writing Agent uses latexEditText, latexSyncCitations for 10-paper reviews, latexCompile for outcome tables, and exportMermaid for revascularization flowcharts.
Use Cases
"Analyze renal function changes pre/post-stenting from 5 papers using statistics."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Radermacher 2001, Watson 2000) → runPythonAnalysis (pandas t-tests on creatinine levels) → GRADE grading → CSV export of significance results.
"Write LaTeX review comparing bare-metal vs drug-eluting renal stents."
Synthesis Agent → gap detection → Writing Agent → latexEditText (draft sections) → latexSyncCitations (Trinquart 2010 et al.) → latexCompile → PDF with outcome tables.
"Find code for simulating renal artery stent patency models."
Research Agent → paperExtractUrls (Eirin 2012) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (matplotlib patency curves) → exportMermaid diagram.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ renal stenting papers: searchPapers → citationGraph → DeepScan 7-step analysis with CoVe checkpoints on restenosis claims. Theorizer generates hypotheses on stem cell-enhanced stenting from Eirin et al. (2012) literature synthesis. DeepScan verifies Doppler index thresholds across Radermacher et al. (2001) and Rees et al. (1991).
Frequently Asked Questions
What defines renal stent placement outcomes?
Outcomes measure restenosis rates, renal function via creatinine/GFR, blood pressure control, and complications like elastic recoil post-procedure (Watson et al., 2000; Rees et al., 1991).
What methods assess stent efficacy?
Doppler ultrasonography with resistance index ≥80 predicts poor response; intermediate-term follow-up tracks patency and renal size (Radermacher et al., 2001; O’Laughlin et al., 1993).
What are key papers on renal stenting?
Radermacher et al. (2001, 772 citations) on Doppler prediction; Watson et al. (2000, 257 citations) on renal function post-stenting; Rees et al. (1991, 249 citations) on Palmaz ostial stents.
What open problems exist?
Optimal patient selection for fibromuscular dysplasia stenting; long-term patency in comorbid CKD; adjuncts like MSCs for atherosclerotic cases (Trinquart et al., 2010; Eirin et al., 2012).
Research Renal and Vascular Pathologies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Renal Stent Placement Outcomes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Renal and Vascular Pathologies Research Guide